The Dual Incretin
Tirzepatide · Injection
A dual GIP and GLP-1 receptor agonist studied for appetite regulation, insulin sensitivity, and sustainable body-weight reduction.
All doses $299 / mo
Benefits.
- Studied for clinically significant body-weight reduction (SURMOUNT trial program)
- Targets both GIP and GLP-1 receptors for amplified metabolic effect
- Researched for improvements in fasting glucose and HbA1c
- Explored for cardiometabolic markers and inflammation
- May reduce food noise and cravings between meals
How it works.
Step 01
Tirzepatide is a synthetic peptide engineered to activate both GIP and GLP-1 receptors.
Step 02
GLP-1 receptor activation slows gastric emptying and increases satiety.
Step 03
GIP receptor activation enhances insulin secretion and modulates fat metabolism.
Step 04
The dual mechanism produces stronger weight and metabolic outcomes than GLP-1 alone.
For educational reference only — not medical advice. Loop does not diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Your protocol is built with a licensed Loop clinician based on your goals, history, and labs.